Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority…

Overview of attention for article published in The Lancet, February 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 6 news outlets
blogs: 1 blog
policy: 5 policy sources
twitter: 29 X users
patent: 16 patents

peer_reviews: 1 peer review site
facebook: 6 Facebook pages
wikipedia: 5 Wikipedia pages
f1000: 1 research highlight platform

Citations

dimensions_citation: 1232 Dimensions

Readers on

mendeley: 711 Mendeley
citeulike: 1 CiteULike

Summary News Blogs Policy documents X Patents Peer reviews Facebook Wikipedia Research highlights Dimensions citations

So far, Altmetric has seen 5 citations on 5 Wikipedia pages.

Leucèmia limfocítica crònica

Cited by user Trollramsac on 20 Jun 2020

Linfoma mantellare

Cited by user IndyJr on 20 Apr 2019

Мантийноклеточная лимфома

Cited by user Роман Беккер on 06 Sep 2014

Mantle cell lymphoma

Cited by user Chris Capoccia on 13 Jul 2014

Mantle cell lymphoma (MCL) is one of the rarest of the non-Hodgkin's lymphomas (NHLs), comprising about 6% of NHL cases.

This page shows the most recent Wikipedia articles that mention this research output.

Click here to find out how to access more activity, including 1 additional Wikipedia articles.